{
    "clinical_study": {
        "@rank": "36694", 
        "arm_group": [
            {
                "arm_group_label": "HemaMax", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous dose of HemaMax"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single subcutaneous dose of Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of\n      HemaMax in healthy male and female volunteers."
        }, 
        "brief_title": "Safety and Tolerability of HemaMax\u2122 (rHuIL-12) as Radiation Countermeasure", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hematopoietic Syndrome Due to Acute Radiation Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Radiation Injuries", 
                "Acute Radiation Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and Female subjects, who have signed the informed consent form must meet all of\n             the following criteria\n\n               1. 18 to 45 years of age\n\n               2. Body mass index (BMI) > 19 and < 0 kg/m2\n\n               3. Normal ECG, vital signs and laboratory test results\n\n               4. Use of effective birth control method and abstinence from sex\n\n               5. Negative pregnancy test and drug screen\n\n        Exclusion Criteria:\n\n          -  Subjects with any of the following characteristics will be considered ineligible:\n\n               1. History of clinically significant renal, hepatic pulmonary, cardiovascular,\n                  cerebrovascular, gastrointestinal, metabolic, hematological, endocrine,\n                  urological, immunological, neurologic or psychiatric disorders or connective\n                  tissue disease\n\n               2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen\n                  (HBsAg) or Hepatitis C antibody, tuberculosis (TB)\n\n               3. Current drug or alcohol addiction\n\n               4. History of clinically significant allergy of any kind\n\n               5. Prior use of IL-12 or HemaMax\n\n               6. Use of any approved or investigational biologic agents or vaccinations  of any\n                  kind in last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742221", 
            "org_study_id": "2012-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "HemaMax", 
                "Placebo"
            ], 
            "description": "Placebo", 
            "intervention_name": "HemaMax", 
            "intervention_type": "Biological", 
            "other_name": "rHuIL-12"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Safety and Tolerability, Cytokines, Acute Radiation Syndrome, Hematopoietic Syndrome, Radiation Countermeasure", 
        "lastchanged_date": "April 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Covance Clinical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax\u2122 (rHuIL-12) in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Covance Clinical Research Unit", 
            "last_name": "Nicholas Siebers, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of subjects with adverse events as a measure of safety and tolerability", 
            "measure": "To determine the safety and tolerability of HemaMax in healthy subjects.", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate PK parameters AUC, Cmax, Tmax, t \u00bd, Vz/F, and CL/F for HemaMax. To evaluate biological response parameters following HemaMax.", 
            "measure": "To characterize the pharmacokinetics, pharmacodynamics and immunogenicity of HemaMax in healthy subjects", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Neumedicines Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Health and Human Services", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Neumedicines Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}